A detailed history of Geode Capital Management, LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 735,533 shares of GLUE stock, worth $3.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
735,533
Previous 687,671 6.96%
Holding current value
$3.03 Million
Previous $3.89 Million 33.46%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$4.26 - $8.46 $203,892 - $404,912
47,862 Added 6.96%
735,533 $5.19 Million
Q4 2023

Feb 13, 2024

BUY
$2.5 - $5.93 $100,457 - $238,285
40,183 Added 6.21%
687,671 $3.89 Million
Q3 2023

Nov 13, 2023

BUY
$4.78 - $7.22 $163,748 - $247,335
34,257 Added 5.59%
647,488 $3.1 Million
Q2 2023

Aug 11, 2023

BUY
$4.53 - $8.4 $136,543 - $253,192
30,142 Added 5.17%
613,231 $4.2 Million
Q1 2023

May 15, 2023

BUY
$5.95 - $8.21 $117,464 - $162,081
19,742 Added 3.5%
583,089 $4.54 Million
Q4 2022

Feb 13, 2023

BUY
$6.71 - $9.72 $223,006 - $323,044
33,235 Added 6.27%
563,347 $4.29 Million
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $1.09 Million - $1.85 Million
152,109 Added 40.24%
530,112 $4.33 Million
Q2 2022

Aug 12, 2022

BUY
$6.15 - $14.99 $125,017 - $304,716
20,328 Added 5.68%
378,003 $3.66 Million
Q1 2022

May 13, 2022

BUY
$10.36 - $20.41 $1.47 Million - $2.89 Million
141,674 Added 65.59%
357,675 $5.01 Million
Q4 2021

Feb 11, 2022

BUY
$16.28 - $27.15 $329,149 - $548,918
20,218 Added 10.33%
216,001 $4.41 Million
Q3 2021

Nov 12, 2021

BUY
$18.59 - $42.21 $3.64 Million - $8.26 Million
195,783 New
195,783 $4.36 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $192M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.